Belal Haschimi

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 13

Top Topics

Liquid Chromatography

High Resolution Mass Spectrometry

Simultaneous Determination

Top Venues

Drug testing and analysis

Drug metabolism and disposition: the biological fate of chemicals

This page only lists publications with an associated author ORCID identifier.

Publications

Arianna Giorgetti, Annette Zschiesche, Olwen Groth, Belal Haschimi, Martin Scheu, Guido Pelletti, Paolo Fais, Frank Musshoff, Volker Auwärter
ADB-HEXINACA-a novel synthetic cannabinoid with a hexyl substituent: phase I metabolism in authentic urine samples, a case report and prevalence on the German market. Drug testing and analysis (2024)
Belal Haschimi, Florian Willecke, Stefan Mundinger, Wolfgang Hüttel, Henning Jessen, Michael Müller, Volker Auwärter
Enzymatic defluorination of a terminally monofluorinated pentyl moiety: oxidative or hydrolytic mechanism? Drug metabolism and disposition: the biological fate of chemicals (2024)
Ascanio Sirignano, Diletta Berardinelli, Arianna Giorgetti, Hannes Max Schwelm, Belal Haschimi, Susi Pelotti, Francesco Paolo Busardò, Volker Auwärter
Human metabolism and basic pharmacokinetic evaluation of AP-238: A recently emerged acylpiperazine opioid. Drug testing and analysis (2023)
Arianna Giorgetti, Ascanio Sirignano, Belal Haschimi, Francesco Paolo Busardò, Susi Pelotti, Volker Auwärter
Human phase-I metabolism and prevalence of two synthetic cannabinoids bearing an ethyl ester moiety: 5F-EDMB-PICA and EDMB-PINACA. Drug testing and analysis (2022)
Katharina Elisabeth Grafinger, Marthe M Vandeputte, Annelies Cannaert, Adam Ametovski, Eric Sparkes, Elizabeth Cairns, Patrick Osamu Juchli, Belal Haschimi, Benedikt Pulver, Samuel D Banister, Christophe Pol Stove, Volker Auwärter
Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB-4en-PICA, MDMB-4en-PINACA, ADB-4en-PINACA, and MMB-4CN-BUTINACA using a combination of binding and different CB1 receptor activation assays. Part III: The G protein pathway and critical comparison of different assays. Drug testing and analysis 13 (7) (2021)
Belal Haschimi, Katharina Elisabeth Grafinger, Benedikt Pulver, Evangelia Psychou, Sebastian Halter, Laura M Huppertz, Folker Westphal, Michael Pütz, Volker Auwärter
New synthetic cannabinoids carrying a cyclobutyl methyl side chain: Human Phase I metabolism and data on human cannabinoid receptor 1 binding and activation of Cumyl-CBMICA and Cumyl-CBMINACA. Drug testing and analysis 13 (8) (2021)
Arianna Giorgetti, Rossella Barone, Guido Pelletti, Marco Garagnani, Jennifer Pascali, Belal Haschimi, Volker Auwärter
Development and validation of a rapid LC-MS/MS method for the detection of 182 novel psychoactive substances in whole blood. Drug testing and analysis (2021)
Caitlyn Norman, Sebastian Halter, Belal Haschimi, Dean Acreman, Josie Smith, Alex J Krotulski, Amanda L A Mohr, Barry K Logan, Niamh Nic Daéid, Volker Auwärter, Craig McKenzie
A transnational perspective on the evolution of the synthetic cannabinoid receptor agonists market: Comparing prison and general populations. Drug testing and analysis 13 (4) (2021)
Sebastian Halter, Belal Haschimi, Lukas Mogler, Volker Auwärter
Impact of legislation on NPS markets in Germany - The rise and fall of 5F-ADB. Drug testing and analysis 12 (6) (2020)
Florian Franz, Belal Haschimi, Leslie A King, Volker Auwärter
Extraordinary long detection window of a synthetic cannabinoid metabolite in human urine - Potential impact on therapeutic decisions. Drug testing and analysis 12 (3) (2020)
Sebastian Halter, Benedikt Pulver, Maurice Wilde, Belal Haschimi, Folker Westphal, Jan Riedel, Michael Pütz, Torsten Schönberger, Stefanie Stoll, Jan Schäper, Volker Auwärter
Cumyl-CBMICA: A new synthetic cannabinoid receptor agonist containing a cyclobutyl methyl side chain. Drug testing and analysis 13 (1) (2020)
Belal Haschimi, Lukas Mogler, Sebastian Halter, Arianna Giorgetti, Bernd Schwarze, Folker Westphal, Svenja Fischmann, Volker Auwärter
Detection of the recently emerged synthetic cannabinoid 4F-MDMB-BINACA in "legal high" products and human urine specimens. Drug testing and analysis 11 (9) (2019)
Arianna Giorgetti, Lukas Mogler, Belal Haschimi, Sebastian Halter, Florian Franz, Folker Westphal, Svenja Fischmann, Jan Riedel, Michael Pütz, Volker Auwärter
Detection and phase I metabolism of the 7-azaindole-derived synthetic cannabinoid 5F-AB-P7AICA including a preliminary pharmacokinetic evaluation. Drug testing and analysis 12 (1) (2019)